Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aurora Cannabis Inc. is a Canadian-based cannabis company operating primarily in the medical cannabis and consumer cannabis industries, with an increasing strategic emphasis on pharmaceutical-grade medical cannabis. The company is engaged in the production, distribution, and sale of cannabis and cannabis-derived products, including dried flower, oils, capsules, edibles, and inhalable formats. Its primary revenue drivers are global medical cannabis sales, complemented by a reduced but ongoing presence in the Canadian adult-use market.
Aurora serves medical patients, provincial distributors, and international healthcare systems, with a particular focus on high-margin medical channels in Canada, Europe, and Australia. The company positions itself as a science-driven producer with strong genetics, GMP-certified manufacturing, and international regulatory expertise. Founded in 2006 as Aurora Medical Marijuana Inc., the company expanded rapidly through acquisitions and capacity buildout between 2016 and 2019, then underwent significant restructuring after 2020 to reduce debt, exit low-margin assets, and refocus on profitability and medical cannabis leadership.
Business Operations
Aurora operates through distinct medical and consumer cannabis business lines, with revenue generated primarily from the sale of cannabis products to registered patients, pharmacies, wholesalers, and provincial distributors. Its core operations include Aurora Medical for Canadian medical sales, Aurora Deutschland and Aurora Nordic for European medical distribution, and MedReleaf Australia for the Australian market. The company also maintains a streamlined Canadian consumer cannabis portfolio sold through provincial boards.
The company controls large-scale cultivation, processing, and distribution assets, including EU-GMP–certified facilities such as Aurora Nordic in Denmark and Canadian production sites like Aurora Sky and Aurora River. Aurora has exited or divested several legacy assets and subsidiaries as part of its restructuring. Its international operations rely on local subsidiaries rather than joint ventures, while partnerships are primarily commercial distribution agreements with pharmacies, hospitals, and national medical cannabis programs.
Strategic Position & Investments
Aurora’s strategic direction centers on becoming a global leader in high-quality, regulated medical cannabis, prioritizing profitability, cash flow generation, and balance sheet strength over volume growth. Growth initiatives include expanding patient enrollment in core medical markets, increasing physician engagement, and developing differentiated medical formulations supported by clinical data. The company has also invested in automation, genetic optimization, and cost-reduction initiatives to improve margins.
Major historical acquisitions include MedReleaf Corp., CanniMed Therapeutics Inc., and ICC Labs, which collectively expanded Aurora’s medical expertise and international footprint. In recent years, the company has shifted away from large-scale acquisitions, focusing instead on organic growth and selective investment in pharmaceutical-grade cannabis, novel cannabinoids, and medical research. Data on material new equity investments or large acquisitions beyond this strategy is inconclusive based on available public sources.
Geographic Footprint
Aurora Cannabis is headquartered in Canada, with its corporate office in Edmonton, Alberta, and operates across multiple continents. Its strongest market presence is in Canada and Europe, where it supplies medical cannabis to countries including Germany, Poland, Denmark, and the United Kingdom. The company also has established operations in Australia and limited exposure to other international medical markets through export arrangements.
International influence is driven primarily through wholly owned subsidiaries and EU-GMP–certified production, enabling Aurora to participate in tightly regulated medical cannabis systems. While Aurora previously held assets or licenses in Latin America and other regions, many of these were divested as part of its strategic retrenchment, resulting in a more concentrated and disciplined geographic footprint.
Leadership & Governance
Aurora is led by an executive team focused on operational discipline, regulatory compliance, and long-term medical cannabis leadership. Governance emphasizes financial controls, risk management, and alignment with international pharmaceutical standards following the company’s restructuring period.
Key executives include:
- Miguel Martin – Chief Executive Officer
- Chris Aiken – Chief Financial Officer
- Dr. Andr� Jerome – Executive Vice President, Global Medical
- Geoff Hoover – Chief Integration Officer
- Ian Simpson – President, Canadian Consumer
The company was originally founded by Terry Booth, who previously served as Chief Executive Officer during Aurora’s early expansion phase. Current leadership articulates a strategy centered on sustainable growth, scientific credibility, and disciplined capital allocation rather than market share expansion at any cost.